Literature DB >> 19815912

Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection.

L Calza1, G Verucchi, D Pocaterra, M Pavoni, A Alfieri, A Cicognani, R Manfredi, C Serra, F Chiodo.   

Abstract

A cross-sectional study was performed to evaluate classical risk factors for cardiovascular diseases and subclinical atherosclerosis by carotid ultrasonography in HIV-positive subjects, naïve or treated with antiretroviral agents. A total of 66 patients were enrolled into the study: 21 subjects were naïve to all antiretroviral agents (group A) and 45 patients were treated with antiretroviral therapy for >or=36 months (group B). The prevalence of carotid plaques was significantly higher in group B than in group A (44.7% versus 0%; P = 0.014). In group B, patients with high 10-year risk of coronary heart disease showed a significantly higher intima-media thickness and prevalence of carotid lesions than those with low risk. Moreover, carotid lesions were structurally comparable to classical atherosclerotique plaques observed in the general population, with iso-hyperechonegic aspects and irregular surfaces. The prevalence of carotid atherosclerosis in experienced patients is higher than in those naïve to highly active antiretroviral therapy and seems mostly associated with a longer duration of HIV infection, more severe lipid metabolism alterations, presence of lipodystrophy syndrome and a more elevated 10-year risk of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815912     DOI: 10.1258/ijsa.2009.008504

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  1 in total

1.  The Evaluation of Carotid Atherosclerosis in Patients with the HIV-1 Infection: The Role of the Antiretroviral Therapy.

Authors:  Suparna P N; Basavaprabhu Achappa; Unnikrishnan B; Deepak Madi; Mukta N Chowta; John T Ramapuram; Satish Rao; Soundarya Mahalingam
Journal:  J Clin Diagn Res       Date:  2013-02-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.